Nurix Therapeutics to Participate in Upcoming Investor Conferences
06 Marzo 2024 - 10:00PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced that Hans van Houte, Nurix’s chief
financial officer, and Jason Kantor, Ph.D., Nurix’s chief business
officer will participate in the following conferences in March:
- Leerink Partners Global
Biopharma Conference 2024One-on-one meetings only:
Tuesday, March 12, 2024
- Barclays Global Healthcare
ConferenceFireside chat: Wednesday, March 13, 2024, from
4:05 – 4:30 p.m. ET
The fireside chat will be webcast live and may be accessed via a
link in the Investors section of the Nurix website under Events and
Presentations. The archived webcast will be available on the Nurix
website for 30 days after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Grafico Azioni Nurix Therapeutics (NASDAQ:NRIX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Nurix Therapeutics (NASDAQ:NRIX)
Storico
Da Giu 2023 a Giu 2024